We are live on ! Find out more
HOWL icon

Werewolf Therapeutics

71 hedge funds and large institutions have $79.2M invested in Werewolf Therapeutics in 2024 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 24 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,267% more call options, than puts

Call options by funds: $131K | Put options by funds: $3K

83% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 12

71% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 14

16% more funds holding

Funds holding: 6171 (+10)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0.75% less ownership

Funds ownership: 75.46%74.71% (-0.75%)

62% less capital invested

Capital invested by funds: $209M → $79.2M (-$130M)

Holders
71
Holders Change
+10
Holders Change %
+16.39%
% of All Funds
1.03%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
22
Increased
24
Reduced
14
Closed
12
Calls
$131K
Puts
$3K
Net Calls
+$128K
Net Calls Change
+$323K
Name Holding Trade Value Shares
Change
Change in
Stake
Dimensional Fund Advisors
26
Dimensional Fund Advisors
Texas
$392K +$235K +48,952 +44%
Marshall Wace
27
Marshall Wace
United Kingdom
$327K +$518K +107,900 +411%
RA
28
Royce & Associates
New York
$306K +$423K +88,163 +236%
BCM
29
Bridgeway Capital Management
Texas
$305K +$192K +40,000 +47%
Walleye Capital
30
Walleye Capital
New York
$240K +$473K +98,440 New
Charles Schwab
31
Charles Schwab
California
$192K +$379K +78,842 New
Bank of New York Mellon
32
Bank of New York Mellon
New York
$165K +$325K +67,644 New
Citadel Advisors
33
Citadel Advisors
Florida
$156K +$292K +60,881 +1,981%
M
34
Murchinson
Ontario, Canada
$153K +$300K +62,500 New
Northern Trust
35
Northern Trust
Illinois
$143K +$48.5K +10,096 +21%
Goldman Sachs
36
Goldman Sachs
New York
$127K -$580K -120,705 -70%
N
37
Nuveen
North Carolina
$127K +$250K +52,048 New
Edgewood Management
38
Edgewood Management
Connecticut
$122K
Morgan Stanley
39
Morgan Stanley
New York
$120K +$137K +28,433 +138%
Man Group
40
Man Group
United Kingdom
$109K -$169K -35,158 -44%
New York State Common Retirement Fund
41
New York State Common Retirement Fund
New York
$97.4K +$192K +39,900 New
American Century Companies
42
American Century Companies
Missouri
$91.8K +$60.8K +12,656 +51%
AGM
43
Alpine Global Management
New York
$91.6K +$180K +37,551 New
BFM
44
Boothbay Fund Management
New York
$91.5K +$180K +37,500 New
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$79.4K +$156K +32,547 New
Jane Street
46
Jane Street
New York
$69.7K -$618K -128,646 -82%
CSS
47
Cubist Systematic Strategies
Connecticut
$69.2K -$59K -12,278 -30%
Barclays
48
Barclays
United Kingdom
$58.1K +$105K +21,942 +1,168%
TRCT
49
Tower Research Capital (TRC)
New York
$58K +$63.5K +13,230 +126%
JF
50
Jump Financial
Illinois
$51.5K +$101K +21,099 New

HOWL Hedge Fund Activity: Q2 2024 in Review

71 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q2 2024, worth a combined $79.2M — down 62% from $209M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new HOWL positions and 12 closed out — a net gain of 10 holders — while 24 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock, adding an estimated $6.83M. The largest seller was Janus Henderson Group, cutting an estimated $7.3M.

  • 71 institutional investors held Werewolf Therapeutics (HOWL) as of Q2 2024, up from 61 in Q1 2024.
  • Funds reported $79.2M of Werewolf Therapeutics stock for Q2 2024, down 62% quarter-over-quarter.
  • 22 funds opened new Werewolf Therapeutics positions in Q2 2024 and 12 closed out, a net change of +10 holders.
  • The largest Werewolf Therapeutics buyer in Q2 2024 was BlackRock, an estimated $6.83M added.
  • The largest Werewolf Therapeutics seller in Q2 2024 was Janus Henderson Group, an estimated $7.3M sold.

Based on aggregated 13F filings for Q2 2024.